FY2024 Earnings Forecast for NuCana Issued By William Blair

NuCana plc (NASDAQ:NCNA) – Analysts at William Blair raised their FY2024 EPS estimates for shares of NuCana in a research note issued to investors on Monday, November 25th. William Blair analyst M. Phipps now expects that the company will earn ($12.76) per share for the year, up from their previous forecast of ($15.75). William Blair has a “Market Perform” rating on the stock. The consensus estimate for NuCana’s current full-year earnings is ($13.20) per share. William Blair also issued estimates for NuCana’s Q4 2024 earnings at ($2.23) EPS, Q1 2025 earnings at ($2.23) EPS, Q2 2025 earnings at ($2.23) EPS, Q3 2025 earnings at ($2.23) EPS, Q4 2025 earnings at ($2.23) EPS, FY2025 earnings at ($9.57) EPS and FY2026 earnings at ($28.70) EPS.

Separately, Oppenheimer lowered their target price on NuCana from $150.00 to $25.00 and set an “outperform” rating for the company in a report on Tuesday, September 3rd.

NuCana Stock Performance

Shares of NASDAQ:NCNA opened at $1.29 on Thursday. NuCana has a 52-week low of $1.23 and a 52-week high of $19.41. The company has a market capitalization of $3.41 million, a PE ratio of -0.11 and a beta of 1.03. The company has a fifty day moving average of $1.86 and a 200-day moving average of $3.08.

Hedge Funds Weigh In On NuCana

A hedge fund recently bought a new stake in NuCana stock. Glass Jacobson Investment Advisors llc acquired a new position in NuCana plc (NASDAQ:NCNA) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 15,000 shares of the company’s stock, valued at approximately $38,000. Glass Jacobson Investment Advisors llc owned about 0.57% of NuCana as of its most recent SEC filing. Hedge funds and other institutional investors own 44.00% of the company’s stock.

About NuCana

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells.